cyc 202 has been researched along with tolvaptan in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 967 | 172 | 786 |
| Protein | Taxonomy | cyc 202 (IC50) | tolvaptan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.99 | |
| Vasopressin V2 receptor | Homo sapiens (human) | 0.1486 | |
| Vasopressin V1a receptor | Homo sapiens (human) | 0.351 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MY; Ong, AC | 1 |
1 review(s) available for cyc 202 and tolvaptan
| Article | Year |
|---|---|
Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
Topics: Aniline Compounds; Antihypertensive Agents; Benzazepines; Clinical Trials as Topic; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Depression, Chemical; Disease Management; Double-Blind Method; Drugs, Investigational; Forecasting; Histone Deacetylase Inhibitors; Humans; Multicenter Studies as Topic; Nitriles; Polycystic Kidney, Autosomal Dominant; Purines; Quinolines; Randomized Controlled Trials as Topic; Roscovitine; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases; Translational Research, Biomedical | 2012 |